Patents by Inventor Keld Fosgerau

Keld Fosgerau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
    Patent number: 10406207
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes related diseases or disorders.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: September 10, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Martensson, Marianne Brorson, Kamilla Rolsted
  • Glucagon analogues
    Patent number: 10253081
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 9, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
  • GLUCAGON ANALOGUES
    Publication number: 20190055296
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: May 18, 2018
    Publication date: February 21, 2019
    Inventors: Jakob Lind TOLBORG, Keld FOSGERAU, Pia NØRREGAARD, Rasmus JUST, Ditte RIBER, Dieter Wolfgang HAMPRECHT, Robert AUGUSTIN, Leo THOMAS, Wolfgang RIST
  • Glucagon analogues
    Patent number: 9975939
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: May 22, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
  • GLP-1 receptor agonist peptide gastrin conjugates
    Patent number: 9861706
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: January 9, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Trine Skovlund Ryge Neerup, Keld Fosgerau, Torben Østerlund, Dorthe Lennert Christensen Almholt, Lone Frost Larsen
  • PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE
    Publication number: 20170281709
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes related diseases or disorders.
    Type: Application
    Filed: December 16, 2016
    Publication date: October 5, 2017
    Inventors: Trine Skovlund Ryge NEERUP, Torben ØSTERLUND, Jakob Lind TOLBORG, Keld FOSGERAU, Ulrika MARTENSSON, Marianne BRORSON, Kamilla ROLSTED
  • Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
    Patent number: 9649362
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: May 16, 2017
    Assignee: Zealand Pharma A/S
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Martensson, Marianne Brorson, Kamilla Rolsted
  • PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE
    Publication number: 20160184400
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Application
    Filed: June 10, 2015
    Publication date: June 30, 2016
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Martensson, Marianne Brorson, Kamilla Rolsted
  • GLP-1 RECEPTOR AGONIST PEPTIDE GASTRIN CONJUGATES
    Publication number: 20160082118
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 24, 2016
    Inventors: Jakob Lind TOLBORG, Trine Skovlund Ryge NEERUP, Keld FOSGERAU, Torben ØSTERLUND, Dorthe Lennert Christensen ALMHOLT, Lone Frost LARSEN
  • GLP-1 receptor agonist peptide gastrin conjugates
    Patent number: 9259477
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: February 16, 2016
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Trine Skovlund Ryge Neerup, Keld Fosgerau, Torben Østerlund, Dorthe Lennert Christensen Almholt, Lone Frost Larsen
  • GLUCAGON ANALOGUES
    Publication number: 20160009777
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: September 24, 2015
    Publication date: January 14, 2016
    Inventors: Jakob Lind TOLBORG, Keld FOSGERAU, Pia NØRREGAARD, Rasmus JUST, Ditte RIBER, Dieter Wolfgang HAMPRECHT, Robert AUGUSTIN, Leo THOMAS, Wolfgang RIST
  • COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES
    Publication number: 20160000883
    Abstract: The invention relates to methods for treating metabolic disorders, including diabetes by using a combination of an acylated glucagon analogue and an insulin analogue. The invention also features a kit that includes an acylated glucagon analogue and an insuline analogue.
    Type: Application
    Filed: September 17, 2015
    Publication date: January 7, 2016
    Inventors: Keld FOSGERAU, Ditte RIBER
  • Glucagon analogues
    Patent number: 9180169
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: November 10, 2015
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
  • Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
    Patent number: 9089538
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: July 28, 2015
    Assignee: Zealand Pharma A/S
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Mårtensson, Marianne Brorson, Kamilla Rolsted
  • GLUCAGON ANALOGUES
    Publication number: 20140080757
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: September 17, 2013
    Publication date: March 20, 2014
    Applicants: Boehringer Ingelheim International GmbH, Zealand Pharma A/S
    Inventors: Jakob Lind TOLBORG, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas
  • COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES
    Publication number: 20140011733
    Abstract: The invention relates to methods for treating metabolic disorders, including diabetes by using a combination of an acylated glucagon analogue and an insulin analogue. The invention also features a kit that includes an acylated glucagon analogue and an insuline analogue.
    Type: Application
    Filed: January 20, 2012
    Publication date: January 9, 2014
    Applicant: Zealand Pharma A/S
    Inventors: Keld Fosgerau, Ditte Riber
  • TREATMENT OF CARDIAC CONDITIONS
    Publication number: 20130157953
    Abstract: The invention relates to the treatment of cardiac dysfunction. In particular, certain compounds, believed to be glucagon-GLP-1 dual agonist compounds, exert a positive inotropic effect while preserving the energy balance of the heart, and so may be superior to known inotropic agents such as dobutamine, norepinephrine and glucagon.
    Type: Application
    Filed: January 20, 2011
    Publication date: June 20, 2013
    Applicant: Zealand Pharma A/S
    Inventors: Jørgen Søberg Petersen, Anne Louise Kjoelbye, Marie Skovgaard, Henrik Duelund Pedersen, Lene Axelsen, Ditte Riber, Eddi Meier, Rie Schultz Hansen, Keld Fosgerau, Bjarne Due Larsen
  • PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE
    Publication number: 20130143793
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Application
    Filed: April 27, 2011
    Publication date: June 6, 2013
    Applicant: ZEALAND PHARMA A/S
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Mårtensson, Marianne Brorson, Kamilla Rolsted
  • Use of Liver-Selective Glucokinase Activators
    Publication number: 20080026987
    Abstract: The present invention provides a method of normalizing blood glucose levels in mammals utilizing liver-selective glucokinase activators. The present invention also provides a method of increasing liver metabolism and decreasing apoptosis independent of glucose normalization or hyperglycemic conditions.
    Type: Application
    Filed: June 17, 2005
    Publication date: January 31, 2008
    Applicant: Novo Nordisk A/S
    Inventors: Peter Mackay, James Mackay, Carmen Valcarce-Lopez, Thora Bodvarsdottir, Keld Fosgerau, Marianne Larsen, Per Arkhammar, Philip Wahl